Exendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Darsalia, Vladimer ^a   Hua, Sansan ^b   Larsson, Martin ^a   Mallard, Carina ^b   Nathanson, David ^a   Nyström, Thomas ^a   Sjöholm, Åke ^c,d   Johansson, Maria E ^b   Patrone, Cesare ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d Division of Obstetrics and Gynecology Södertälje Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEURON SPECIFIC NUCLEAR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT; PEPTIDE; VENOM;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; GENE EXPRESSION; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLARIZATION; UPREGULATION; ANIMAL; C57BL MOUSE; CEREBRAL ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG SCREENING; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION PROFILING; METABOLISM; PATHOLOGY; PHENOTYPE; STROKE; TIME;

ANIMALS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE, INBRED C57BL; MICROGLIA; NEUROPROTECTIVE AGENTS; PEPTIDES; PHENOTYPE; STROKE; TIME FACTORS; VENOMS;

EID: 84905493033     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103114     Document Type: Article

References (41)

1. Sohrabji F, Bake S, Lewis DK (2013) Age-related changes in brain support cells: Implications for stroke severity. Neurochem Int 63: 291-301.
2. Sander D, Kearney MT (2009) Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. J Neurol 256: 1603-1619.
3. Wahlgren NG, Ahmed N (2004) Neuroprotection in cerebral ischaemia: facts and fancies-the need for new approaches. Cerebrovasc Dis 17 Suppl 1: 153-166. (Pubitemid 38032534)
4. Rother J (2008) Neuroprotection does not work! Stroke 39: 523-524.
5. Turner RC, Dodson SC, Rosen CL, Huber JD (2013) The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. J Neurosurg 118: 1072-1085.
6. Lansberg MG, Bluhmki E, Thijs VN (2009) Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 40: 2438-2441.
7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333: 1581-1587.
8. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705. (Pubitemid 46048557)
9. Deacon CF (2005) What do we know about the secretion and degradation of incretin hormones? Regul Pept 128: 117-124.
10. Amylin Pharmaceuticals IBeipiAP, Inc. San Diego (CA) USA. (2005).
11. Kastin AJ, Akerstrom V (2003) Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 27: 313-318.
12. Holscher C (2013) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol.
13. Harkavyi A, Whitton PS (2010) Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159: 495-501.
14. Salcedo I, Tweedie D, Li YZ, Greig NH (2012) Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. British Journal of Pharmacology 166: 1586-1599.
15. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, et al. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A 106: 1285-1290.
16. Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, et al. (2012) Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) 122: 473-483.
17. Briyal S, Gulati K, Gulati A (2012) Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res 1427: 23-34.
18. Lee CH, Yan B, Yoo KY, Choi JH, Kwon SH, et al. (2011) Ischemia-Induced Changes in Glucagon-Like Peptide-1 Receptor and Neuroprotective Effect of Its Agonist, Exendin-4, in Experimental Transient Cerebral Ischemia. Journal of Neuroscience Research 89: 1103-1113.
19. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, et al. (2011) Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab.
20. Eltzschig HK, Eckle T (2011) Ischemia and reperfusion-from mechanism to translation. Nat Med 17: 1391-1401.
21. Jin R, Yang G, Li G (2010) Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 87: 779-789.
22. Shichita T, Ago T, Kamouchi M, Kitazono T, Yoshimura A, et al. (2012) Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke. J Neurochem 123 Suppl 2: 29-38.
23. Dirnagl U, Iadecola C, Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22: 391-397. (Pubitemid 29453643)
24. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122: 787-795.
25. Hu X, Li P, Guo Y, Wang H, Leak RK, et al. (2012) Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43: 3063-3070.
26. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA (1996) Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab 16: 605-611. (Pubitemid 26227069)
27. (1997) A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke 28: 1530-1540.
28. California Acute Stroke Pilot Registry I (2005) Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 64: 654-659.
29. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, et al. (2012) Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 79: 306-313.
30. Manning NW, Campbell BC, Oxley TJ, Chapot R (2014) Acute ischemic stroke: time, penumbra, and reperfusion. Stroke 45: 640-644.
31. Gladstone DJ, Black SE, Hakim AM, Heart and Stroke Foundation of Ontario Centre of Excellence in Stroke R (2002) Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33: 2123-2136. (Pubitemid 34840080)
32. Sena E, van der Worp HB, Howells D, Macleod M (2007) How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 30: 433-439. (Pubitemid 47374833)
33. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, et al. (2011) Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev: CD006423.
34. Karapanayiotides T, Piechowski-Jozwiak B, van Melle G, Bogousslavsky J, Devuyst G (2004) Stroke patterns, etiology, and prognosis in patients with diabetes mellitus. Neurology 62: 1558-1562. (Pubitemid 38608195)
35. Steiner I, Gotkine M, Wirguin I (2008) The protective effect of risk factors against stroke severity. J Neurol Sci 267: 187-188.
36. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, et al. (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40: 2244-2250.
37. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, et al. (2004) Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol 187: 94-104. (Pubitemid 38470016)
38. Hamilton A, Holscher C (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport.
39. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J (2006) Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res 55: 352-360. (Pubitemid 43866249)
40. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, et al. (2009) Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29: 13435-13444.
41. Stridh L, Mottahedin A, Johansson ME, Valdez RC, Northington F, et al. (2013) Toll-like receptor-3 activation increases the vulnerability of the neonatal brain to hypoxia-ischemia. J Neurosci 33: 12041-12051.